Senior Management

Søren Bregenholt
CEO
    • Independent in relation to the Company and its management: No
    • Independent in relation to major shareholders: Yes
    • Holdings in Alligator: 908,353 shares, 500,000 warrants in program TO 2022/2025 I, and 1,200,000 warrants in program TO 2023/2026 I.
    • Other current positions: Chairman of Medicon Valley Alliance, Chairman of A Bioscience Incentive AB and Atlas Therapeutics AB, and Board member of Oblique Therapeutics AB (publ).
    Peter Ellmark
    CSO
      • Independent in relation to the Company and its management: No
      • Independent in relation to major shareholders: Yes
      • Holdings in Alligator: 83,720 shares, 250,000 warrants in program TO 2022/2025 I, and 600,000 warrants in program TO 2023/2026 I.
      • Other current positions: None
      Marie Svensson
      CFO
        • Independent in relation to the Company and its management: No
        • Independent in relation to major shareholders: Yes
        • Holdings in Alligator: 251,250 shares, 250,000 warrants in program TO 2022/2025 I, and 600,000 warrants in program TO 2023/2026 I.
        • Other current positions: Board member of A Bioscience Incentive AB and Atlas Therapeutics AB, Deputy board member in Lemniscus Consulting AB.
        Laura von Schantz
        CTO
          • Independent in relation to the Company and its management: No
          • Independent in relation to major shareholders: Yes
          • Holdings in Alligator: 10,504 shares and 77,000 warrants in program TO 2022/2025 I.
          • Other current positions: None
          Dr. Sumeet Ambarkhane
          CMO
            • Independent in relation to the Company and its management: No
            • Independent in relation to major shareholders: Yes
            • Holdings in Alligator: 250,000 warrants in program TO 2022/2025 I.
            • Other current positions: Inga
            Updated 2023-09-05